Accord Logo

Intended for UK patients and members of the public

PIL - Mometasone Furoate 1mg/g Cream: Change history

Back to products
  • View Patient Information Leaflet (PIL - Mometasone Furoate 1mg/g Cream)

    Last updated on this site: 10 Apr 2026

    To update the address of the registered finished product manufacturer, batch release site, QC testing site and primary and secondary packaging site, Tiofarma B.V. from Benjamin Franklinstraat 5-10, 3261 LW Oud-Beijerland, The Netherlands to Hermanus Boerhaavestraat 1, 3261 ME Oud-Beijerland, The Netherlands. The PIL has been updated accordingly.

    View change history

    • Changes: (Updated: 10 Apr 2026)

      To update the address of the registered finished product manufacturer, batch release site, QC testing site and primary and secondary packaging site, Tiofarma B.V. from Benjamin Franklinstraat 5-10, 3261 LW Oud-Beijerland, The Netherlands to Hermanus Boerhaavestraat 1, 3261 ME Oud-Beijerland, The Netherlands. The PIL has been updated accordingly.

    • Changes: (Updated: 10 Mar 2025)

      IAIN, C.I.3.a - To update section 4.8 of the SmPC in line with the MHRA request SA 19259594 for topical mometasone and ADR rosacea. Consequently, the PIL has been updated.

      PIL sections updated: 4 and 6.

    • Changes: (Updated: 14 Aug 2024)

      To update 4.4 of the SmPC and section 1 of PIL for Mometasone Furoate 1mg/g Cream in line with MHRA request letter to update potency labelling of topical corticosteroids, dated 15/01/2024.

    • Changes: (Updated: 04 Dec 2023)

      To update sections 4.4 and 5.1 of the SmPC following MHRA advice to include the topical corticosteroid potency as defined by the ATC code. The PIL has also been updated.

      Additionally, minor amends have been made to the PIL to correct spelling and grammar.

    • Changes: (Updated: 21 Sep 2022)

      Initial upload

    Back to Top

    View product information as a: